Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway

International Journal of Oncology

Volumn 29, Issue 2, 2006, Pages 503-512

  Neuwirt, Hannes ^a   Muller, Hansgeorg ^a   Cavarretta, Ilaria T R ^b   Tiefenthaler, Martin ^a   Bartsch, Georg ^b   Konwalinka, Guenther ^a   Culig, Zoran ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Akacid medical formulation; Cell cycle; Intracellular signaling; Mitogen activated protein kinases; Prostate cancer

Indexed keywords

AKACID MEDICAL FORMULATION; AKACID-MEDICAL-FORMULATION; ANTINEOPLASTIC AGENT; GUANIDINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; ENZYME ACTIVATION; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GUANIDINES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROSTATIC NEOPLASMS; S PHASE;

EID: 33751108181     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.2.503     Document Type: Article

References (53)

1. Albert M, Feiertag P, Hayn G, Saf R and Honig H: Structure-activity relationships of oligoguanidines - influence of counterion, diamine, and average molecular weight on biocidal activities. Biomacromolecules 4: 1811-1817, 2003.
2. Kim BR, Anderson JE, Mueller SA, Gaines WA and Kendall AM: Literature review - efficacy of various disinfectants against Legionella in water systems. Water Res 36: 4433-4444, 2002.
3. Ohta S, Misawa Y, Miyamoto H, Makino M, Nagai K, Shiraishi T, Nakagawa Y, et al: A comparative study of characteristics of current-type and conventional-type cationic bactericides. Biol Pharm Bull 24: 1093-1096, 2001. (Pubitemid 32894137)
4. Broxton P, Woodcock PM, Heatley F and Gilbert P: Interaction of some polyhexamethylene biguanides and membrane phospholipids in Escherichia coli. J Appl Bacteriol 57: 115-124, 1984. (Pubitemid 14037967)
5. Chawner JA and Gilbert PJ: Interaction of the bisbiguanides chlorhexidine and alexidine with phospholipid vesicles: evidence for separate modes of action. J Appl Bacteriol 66: 253-258, 1989.
6. Feiertag P, Albert M, Ecker-Eckhofen EM, Hayn G, Hönig H, Oberwalder HW, Saf R, et al: Structural characterization of biocidal oligoguanidines. Macromol Rapid Commun 24: 567-570, 2003.
7. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972-3982, 2002.
8. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
9. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
10. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, et al: Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81: 242-251, 1999. (Pubitemid 29423702)
11. Wang LG, Ossowski L and Ferrari AC: Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 61: 7544-7551, 2001. (Pubitemid 32995046)
12. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, et al: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-669, 1992.
13. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS and Wilson EM: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319, 2001. (Pubitemid 32685750)
14. Culig Z, Klocker H, Bartsch G, Steiner H and Hobisch A: Androgen receptors in prostate cancer. J Urol 170: 1363-1369, 2003.
15. Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285, 1999. (Pubitemid 29124362)
16. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994. (Pubitemid 24978134)
17. Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, Vicentini C and Bologna M: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the non-steroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 115: 630-640, 2005. (Pubitemid 40656723)
18. Zhang XQ, Lee MS, Zelivianski S and Lin MF: Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J Biol Chem 276: 2544-2550, 2001. (Pubitemid 37376627)
19. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999. (Pubitemid 29048852)
20. Bakin RE, Gioeli D, Sikes RA, Bissonette EA and Weber MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63: 1981-1989, 2003.
21. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, et al: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-24505, 2000. (Pubitemid 30626543)
22. Liao Y, Grobholz R, Abel U, Trojan L, Michel MS, Angel P and Mayer D: Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer 107: 676-680, 2003. (Pubitemid 37296133)
23. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, et al: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601, 2004. (Pubitemid 38796850)
24. Uzgare AR and Isaacs JT: Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 64: 6190-6199, 2004.
25. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
26. Boabang P, Kurbacher CM, Kohlhagen H, Waida A and Amo-Takyi BK: Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay. Anticancer Drugs 11: 843-848, 2000.
27. Pedrazzini E, Mamaev N, Yakovleva T, Sukhikh T, Salido M, Sole F, Prat E, et al: Genomic rearrangements involving rDNA and centromeric heterochromatin in vulvar epidermoid carcinoma cell line A-431. Cancer Genet Cytogenet 143: 50-58, 2003. (Pubitemid 36549007)
28. Garikapaty VP, Ashok BT, Tadi K, Mittelman A and Tiwari RK: Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate 66: 453-462, 2005.
29. Arunkumar A, Vijayababu MR, Kanagaraj P, Balasubramanian K, Aruldhas MM and Arunakaran J: Growth suppressing effect of garlic compound diallyl disulfide on prostate cancer cell line (PC-3) in vitro. Biol Pharm Bull 28: 740-743, 2005. (Pubitemid 40879949)
30. Gunadharini DN, Arunkumar A, Krishnamoorthy G, Muthuvel R, Vijayababu MR, Kanagaraj P, Srinivasan N, et al: Antiproliferative effect of diallyl disulfide (DADS) on prostate cancer cell line LNCaP. Cell Biochem Funct (In press).
31. Yim D, Singh RP, Agarwal C, Lee S, Chi H and Agarwal R: A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res 65: 1035-1044, 2005. (Pubitemid 40216466)
32. Bedin M, Gaben AM, Saucier C and Mester J: Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. Int J Cancer 109: 643-652, 2004. (Pubitemid 38405609)
33. Srethapakdi M, Liu F, Tavorath R and Rosen N: Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 60: 3940-3946, 2000. (Pubitemid 32204590)
34. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ and Arnold A: The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20: 501-534, 1999. (Pubitemid 30647078)
35. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF and Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559-1571, 1993. (Pubitemid 23234349)
36. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, Doi S, et al: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8: 3447-3457, 1993. (Pubitemid 23342646)
37. Resnitzky D, Gossen M, Bujard H and Reed SI: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14: 1669-1679, 1994. (Pubitemid 24074562)
38. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ and Weinstein IB: Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 35: 95-101, 1998. (Pubitemid 28183291)
39. Chen Y, Martinez LA, La Cava M, Coghlan L and Conti CJ: Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 16: 1913-1920, 1998.
40. Drobnjak M, Osman I, Scher HI, Fazzari M and Cordon-Cardo C: Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 6: 1891-1895, 2000.
41. Ni J, Chen M, Zhang Y, Li R, Huang J and Yeh S: Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 300: 357-363, 2003. (Pubitemid 38375816)
42. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ and Dutta A: Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 56: 4159-4163, 1996. (Pubitemid 26305010)
43. Yamamoto A, Hashimoto Y, Kohri K, Ogata E, Kato S, Ikeda K and Nakanishi M: Cyclin E as a coactivator of the androgen receptor. J Cell Biol 150: 873-880, 2000.
44. Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, et al: A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 24: 431-444, 2005. (Pubitemid 40188591)
45. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, et al: Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209-9216, 2004. (Pubitemid 39665537)
46. Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, et al: Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 201: 97-105, 2004. (Pubitemid 39187048)
47. Ratan HL, Gescher A, Steward WP and Mellon JK: ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 92: 890-895, 2003.
48. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C and Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780-2785, 1991.
49. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, et al: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1: 545-550, 1995.
50. Viala E and Pouyssegur J: Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann NY Acad Sci 1030: 208-218, 2004. (Pubitemid 40378916)
51. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, et al: ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107: 478-485, 2003. (Pubitemid 37266470)
52. Pinelli E, Poux N, Garren L, Pipy B, Castegnaro M, Miller DJ and Pfohl-Leszkowicz A: Activation of mitogen-activated protein kinase by fumonisin B(1) stimulates cPLA(2) phosphorylation, the arachidonic acid cascade and cAMP production. Carcinogenesis 20: 1683-1688, 1999.
53. Tolleson WH, Melchior WB Jr, Morris SM, McGarrity LJ, Domon OE, Muskhelishvili L, James SJ, et al: Apoptotic and anti-proliferative effects of fumonisin B1 in human keratinocytes, fibroblasts, esophageal epithelial cells and hepatoma cells. Carcinogenesis 17: 239-249, 1996. (Pubitemid 26091301)